• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Luc Sterkman
 

Luc Sterkman

on

  • 421 views

 

Statistics

Views

Total Views
421
Views on SlideShare
421
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Luc Sterkman Luc Sterkman Presentation Transcript

    • Lifestyle & Food Voorkomen is het nieuwe genezen Health Valley EventLuc Sterkman 13 maart 2013
    • Nelissen Pluimvee
    • Globus ei BV
    • Prijsvorming 1,4Prijs per kilo 1,2 1 0,8 2003 2004 2005 0,6 0,4 0,2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 Week
    • Zoektocht naar toegevoegde waarde
    • Begin van nieuw leven!
    • Preventie Genetica Voeding Leefstijl Gezondheidszorg
    • Health Valley 2013Health Valley, make health & innovation work!
    • Innovatie
    • Innovatie 2.0
    • Medication NutraceuticalFood
    • Ontwikkelprogramma’sNWT-02 Bioactive peptidesNWT-03 Behoud van cardiovasculaire gezondheidOBESITAS
    • Pharmaceutical approach Aangepast op regelgeving Senior farma medewerkers Klinische studies Product ontwikkeling Kwaliteits standaard – Good Clinical Practice – Good Laboratory Practice – Good Manufacturing Practice
    • New regulation (2006/1924/EC)Voedingsclaims Gezondheidsclaims Art. 13 Art. 14 Art. 13.1 Art. 13.5 Art. 14Bijv. Nutriëntsamenstelling Algemeen Claim op basis - Risico reductie geaccepteerd van ‘nieuw’ - Kinderen wetenschap- bewijs pelijk bewijs
    • Business model
    • Egg yolk is the superior carrier for lutein Chung, HY, et al, J. Nutr. 134:1887-1893, 2004
    • NWT-02 status 2007 2012 2014 PCT National Patents EU filing PCT filing grant authorizations ed EFSA/Regulatory Lab Volunteers People “at risk’’ FDAProduction Lab scale Pilot scale Industrial MarketMarketing definition Product definition Preparations Partnering Sales
    • Clinical trial program Human 1 - pivotal study on visual function 12 months | 100 subjects with early stage AMD Human 2 - study on cholesterol & AMD 3 months | 120 healthy volunteers Human 3 - study on bioavailability of ‘EyePowder’ formulations vs NWT-02 2 months | 100 healthy volunteers Human 4 - pivotal study on visual function 12 months | 120 subjects - early stage AMD
    • NWT-02 results – pilot study Blood lutein level Total Cholesterol 2,00 1,04 1,03 1,80 1,02 Change vs base line Change vs base line Normal egg Normal egg 1,60 1,01 NWT-02 NWT-02 1,00 1,40 NWT-01 (lutein 0,99 NWT-01 (lutein egg) egg) 1,20 Control 0,98 Control 0,97 1,00 0,96 0,80 0,95 0w 6,5 w 13 weeks 0w 6,5 w 13 weeks Time Time
    • Results NWT-02 does very efficiently bring lutein and other valuable nutrients in the blood stream and into the macula. This leads to stabilization (often even improvement) of eye functions such as visual acuity and light- dark adaptation. Although egg yolk is used, there is no or little effect on blood cholesterol.
    • NWT-03: “the new approachfor maintaining (vascular) health”Development of bioactive peptides as functional food or nutraceutical forthe prevention of vascular damage and related disorders
    • NWT-03 Project Hydrolysate – produced via enzymatic treatment of lysozyme, an egg- derived protein Designed based on bioinformatics-model of the University Wageningen; aiming for a beneficial effect on the arterial vascular wall First tested in pharmacology models to confirm the effect and elucidate the mechanisms Subsequently tested in animal experiments: – Confirming reduction in bloodpressure in Hypertensive rats – Demonstrating maintenance of the flexibility of the vascular wall in ZDF-rats, which suffer from Diabetes melllitus; model for ageing
    • NWT-03 status 2006 2012 2015 Patents PCT National EU filing PCT filing granted authorizations Regulatory Lab Animals Volunteers Patients EFSA/ FDA Production Lab scale Pilot scale Industrial Market Marketing definition Product definition Preparations Partnering Sales
    • Acute effects of NWT-03 in SHR-rats
    • Kidney – anatomy and histology Histology (PAS) of a healthy glomerulus
    • Renal morphology in ZDF-rats
    • Glomerulosclerosis and Albuminuria 60 50glomerulosclerosis-score 40 9 controls 30 8 diabetes Albuminurie (mg/24uur) 7 diabetes + NWT-03 20 6 controles 10 5 diabetes 4 diabetes + NWT-03 0 3 2 1 0
    • Sector overschrijdende aanpak Genetica Wetenschap Innovatieve bedrijven Voeding Leefstijl Overheid Gezondheidszorg
    • Preventieve aanpak Diagnostiek Genetica Wetenschap Innovatieve bedrijven Voeding Speciale voeding Leefstijl Overheid Preventiemanagement Gezondheidszorg Zorgverzekeraars
    • Secundaire preventie Vroege diagnostiek Medische technologie – Kan leiden tot – Kan leiden tot Vroege behandeling Diagnostische apparatuur – Met als doel – Met als doel Secundaire preventie Vroege diagnostiek – Gebruik makend van – Gebruik makend van Food Scanning Laser Optics – Milde effecten – Milde methode – Zonder neven effecten – Zonder neven effecten – Op professionele wijze – Op professionele wijze ontwikkeld (farma) ontwikkeld (Qserve)
    • Rol Newtricious
    • Samenwerken
    • Samenwerken en verbinden
    • Virtual company
    • Newtricious “Network” Nateland consultancy Coppelmans VOF
    • BrandRepAroma Uden
    • Strategische investeerders